KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Accrued Expenses

Last Annual Value

1.60M

3-Year CAGR

-15%

5-Year CAGR

-14%

10-Year CAGR

-7%

KT

Kalaris Therapeutics Inc Competitors Analysis of Accrued Expenses

KLRS · NASDAQ
CompanyAccrued Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.60M
16.0%-25.3%N/A 
4.90M
-9.1%5.4%5.5%
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
9.54M
36.9%0.7%14.0%
0.00
N/AN/AN/A
5.65M
17.3%25.0%N/A
0.00
N/AN/AN/A
2.47M
32.7%N/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7